[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hemorrhagic-stroke-intracerebral\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hemorrhagic-stroke-intracerebral":36},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,54,83,108,144],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":37,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":42,"lastUpdatePostDateStruct":43,"startDateStruct":46,"completionDateStruct":48,"leadSponsor":50,"locationsCount":53},"100644087","efficacy-and-safety-of-antihypertensive-treatment-with-mobile-stroke-units-in-ultra-early-intracerebral-hemorrhage-100644087",false,"NCT07665827","Efficacy and Safety of Antihypertensive Treatment With Mobile Stroke Units in Ultra-Early Intracerebral Hemorrhage","Efficacy and Safety of Antihypertensive Treatment With Mobile Stroke Units in Ultra-Early Intracerebral Hemorrhage: A Multicenter, Prospective, Cluster-Randomized, Open-Label, Blinded-Endpoint Clinical Trial","MSU-ICH","Inclusion Criteria:\n\n1. History and physical\u002Fneurological examination consistent with acute stroke.\n2. Age ≥18 years;\n3. Time from symptom onset to enrollment \\\u003C3 hours (onset defined as last known normal).\n4. Systolic blood pressure ≥150 mmHg and ≤220 mmHg;\n5. Pre-stroke modified Rankin Scale (mRS) score ≤2;\n6. Informed consent obtained from the subject or a legally authorized representative.\n\nExclusion Criteria:\n\n1. Glasgow Coma Scale (GCS) score ≤5.\n2. Contraindications to intensive blood pressure lowering, including severe arterial stenosis or high-grade stenotic valvular heart disease.\n3. Malignant disease or other serious primary illness with a life expectancy of \\\u003C3 months.\n4. Current participation in another interventional randomized clinical trial.","ALL","18 Years",{"count":20,"type":21},706,"ESTIMATED","INTERVENTIONAL",[24],"NA","MSU-ICH is a prospective, multicenter, Week-wise-randomized, open-label, blinded-endpoint (PROBE) clinical trial comparing ultra-early prehospital blood pressure lowering delivered by a Mobile Stroke Unit (MSU) with standard Emergency Medical Services (EMS) in patients with spontaneous intracerebral hemorrhage.",[27,28,29,30,31,32,33,34,35,36],"Nervous System Diseases","Cerebrovascular Disorders","Cardiovascular Diseases","Vascular Diseases","Hemorrhage","Intracranial Hemorrhages","Cerebral Hemorrhage","Cerebral Hemorrhage, Hypertensive","Stroke","Hemorrhagic Stroke, Intracerebral",[38,39,40],"intracerebral hemorrhage","mobile stroke units","Intensive blood pressure lowering","NOT_YET_RECRUITING","2026-06-18",{"date":44,"type":45},"2026-06-24","ACTUAL",{"date":47,"type":21},"2026-06",{"date":49,"type":21},"2028-07",{"name":51,"class":52},"Xuanwu Hospital, Beijing","OTHER",1,{"id":55,"slug":56,"hasResults":11,"nctId":57,"briefTitle":58,"officialTitle":58,"acronym":59,"eligibilityCriteria":60,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":61,"targetDuration":4,"studyType":63,"phases":4,"briefSummary":64,"conditions":65,"keywords":4,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":53},"100639950","recovery-trajectory-for-coma-and-disorders-of-consciousness-100639950","NCT07614074","Recovery Trajectory for Coma and Disorders of Consciousness","Coma Cohort","Inclusion Criteria:\n\n* Age greater than or equal to 18 years on the day of hospital admission\n* Coma duration of at least 24 hours from presentation to the receiving hospital, or died prior to the 24 hour timepoint without return of consciousness. Coma defined as: GCS score of less than or equal to 10 AND GCS score of less than 6 on the motor component of the GCS(not following commands) AND GCS score less than 3 on the verbal component AND alteration of consciousness not explained by sedation only\n* Coma due to a neurological process (Including but not limited to: trauma, stroke, hypoxic- ischemic brain injury (HIBI), CNS infection, seizure, other processes at the discretion of the investigator)\n* Admission to the intensive care unit, or deceased prior to admission.\n\nExclusion Criteria:\n\n* Pre-existing score of 5 or less on the motor component of the Glasgow Coma Scale prior to hospital admission.\n* Transfer from another acute care hospital in which the motor component of the Glasgow Coma Scale on the day after initial hospital arrival is not known or cannot be reconstructed from medical records or history.\n* Coma due to sepsis, systemic metabolic processes (ex: organ failure or sedation).\n* GCS score of greater than 2 for eye opening with lack of command following due to a focal brain lesion causing receptive aphasia.\n* Prisoner",{"count":62,"type":21},2000,"OBSERVATIONAL","This study aims to better understand recovery after coma caused by serious neurologic illness or injury. Patients who are unconscious (in a coma or disorder of consciousness) due to conditions such as stroke, cardiac arrest, traumatic brain injury, seizures, brain infection, or other neurologic emergencies may be enrolled during their hospitalization.\n\nThe purpose of this observational research study is to learn which medical, neurologic, psychological, and social factors are associated with recovery over time. Researchers will collect information from the medical record during hospitalization, including details about the patient's illness, treatments received, brain imaging, and neurologic examinations.\n\nFor patients who survive hospitalization, the study team will contact participants or their caregivers after discharge to assess recovery at scheduled time points using questionnaires and structured interviews about physical function, quality of life, emotional well-being, and daily activities.\n\nThis study does not assign participants to any experimental treatment. Participation will not change the medical care patients receive. Information learned from this study may help improve future care for patients with coma and disorders of consciousness.",[66,67,68,69,70,36,71,72],"Coma","Disorders of Consciousness","Cardiac Arrest (CA)","Traumatic Brain Injuries","Ischemic Stroke","Meningitis\u002FEncephalitis","Status Epilepticus","RECRUITING","2026-05-28",{"date":76,"type":45},"2026-06-02",{"date":78,"type":45},"2023-09-26",{"date":80,"type":21},"2033-09",{"name":82,"class":52},"University of California, San Francisco",{"id":84,"slug":85,"hasResults":11,"nctId":86,"briefTitle":87,"officialTitle":88,"acronym":89,"eligibilityCriteria":90,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":91,"targetDuration":4,"studyType":22,"phases":93,"briefSummary":94,"conditions":95,"keywords":4,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":107},"100596943","one-stop-management-for-a-swift-initiation-of-endovascular-therapy-100596943","NCT07052045","One-Stop manaGemEnT For A Swift Initiation of Endovascular Therapy","One-Stop manaGemEnT For A Swift Initiation of Endovascular Therapy - An International, Multicenter, Pragmatic Randomized Controlled Trial (GET-FAST","GET-FAST","Inclusion Criteria:\n\n* Symptoms suggestive of an acute ischemic stroke caused by a large or medium vessel occlusion as defined by a National Institute of Health Stroke Scale (NIHSS) Score of ≥ 10 points\n* Patient presents directly to the treating hospital (mothership patient) within 4.5 hours of last seen well (LSW)\n* Age ≥ 18 years\n* Patient was independent in daily activities prior to the stroke (pre stroke modified Rankin Scale of 0 - 2)\n* Endovascular treatment team available (Neurologist, Interventionist, Anesthesiologist, Nursery, Technicians)\n* Informed Consent as documented by signature or fulfilling the criteria for emergency consent procedures\n\nExclusion Criteria:\n\n* Severe comorbidities, which will likely prevent improvement or follow-up\n* In-hospital stroke\n* Clinical symptoms suggestive of intracranial hemorrhage (deterioration of patient during transport, vomiting or depressed consciousness)\n* Strong suspicion of functional neurological symptom disorder \u002F conversion disorder\n* Hemodynamically unstable patients who require advanced vital support\n* Angiography room occupied by other procedure",{"count":92,"type":21},390,[24],"Stroke, especially acute ischemic stroke (AIS) caused by a blocked blood vessel in the brain, is a leading cause of death and long-term disability. When the blockage is in a large blood vessel, a procedure called endovascular therapy (EVT)-where the clot is removed using a catheter-is highly effective. However, the sooner EVT is done, the better the outcome for the patient.\n\nResearch has shown that delays between arriving at the hospital and starting EVT (called door-to-groin time) significantly reduce the chances of recovery. For example, reducing this time by just 15 minutes can mean 20 more patients (out of 1,000 treated) going home instead of to a care facility. Even a 10-minute improvement can result in over 100 extra days of independent living for patients and save more than $10,000 in healthcare costs per patient.\n\nTo reduce these delays, hospitals have improved stroke workflows. In the current standard approach, patients suspected of having a stroke are taken first to a CT scan room to confirm the diagnosis, and then, if a treatable occlusion is found, to a separate room for EVT. This usually takes around 60-70 minutes.\n\nHowever, moving patients between rooms takes time. A new approach called \"One-Stop management\" could solve this. In this method, both the brain scan and the EVT procedure are done in one room-the angiography suite-using special imaging tools called flat panel CT (FDCT) and FDCT angiography (FDCT-A).\n\nA previous study with 230 patients showed that One-Stop management is possible and saves time. But there's a challenge: the decision to follow the One-Stop pathway is made before a clear diagnosis is available. That's important because not all strokes benefit from EVT. Severe stroke symptoms (measured by a score called NIHSS ≥10) can come from:\n\n* A large or medium vessel blockage (which EVT can treat),\n* A small vessel blockage, or\n* A bleed in the brain (hemorrhage). Only the first group benefits from EVT. About 85% of patients with severe symptoms fall into this category. The rest-about 15%-would not benefit, and there are concerns that FDCT might be slightly less accurate than regular CT in diagnosing these types of strokes. So, we need to test whether One-Stop management is safe and effective for all patients, not just those with treatable blockages.\n\nTo do this, the GET-FAST trial will compare the One-Stop approach to the standard two-room process. Patients will be randomly assigned to one of the two strategies. Importantly, this randomization won't affect their actual treatment-everyone will still receive the best care according to current medical guidelines. The main endpoint for the evaluation of the One-Stop approach will be long-term (at 90 days) disability and dependency in daily life as measured with the modified Rankin Scale (mRS).\n\nThis study will include all patients as they were assigned, regardless of what type of stroke they actually had. This is called an \"intention-to-treat\" analysis, and it provides the most reliable measure of the overall impact of One-Stop management.\n\nAnother key aspect of the trial is that any CE-certified imaging system already used in hospitals can be used for the One-Stop process-no specific brand or model is required. This makes the results more applicable to real-world hospital settings.\n\nIf GET-FAST proves that One-Stop management leads to better patient outcomes, this could transform how stroke care is delivered. More patients could return to independent living, and fewer would require long-term care -leading to major reductions in healthcare costs. For example, even a one-point improvement on a common stroke disability scale (mRS) can triple the savings in lifetime care costs.",[96,97,36],"Stroke Acute","Acute Ischemic Stroke AIS","2026-01-15",{"date":100,"type":45},"2026-01-20",{"date":102,"type":45},"2025-12-02",{"date":104,"type":21},"2028-11-01",{"name":106,"class":52},"Prof. Dr. Jan Liman",2,{"id":109,"slug":110,"hasResults":11,"nctId":111,"briefTitle":112,"officialTitle":112,"acronym":4,"eligibilityCriteria":113,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":114,"targetDuration":4,"studyType":22,"phases":116,"briefSummary":118,"conditions":119,"keywords":125,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":135,"lastUpdatePostDateStruct":136,"startDateStruct":138,"completionDateStruct":140,"leadSponsor":142,"locationsCount":53},"100610247","phase-4-evaluation-of-the-efficacy-of-stratafix-for-neurosurgical-cranial-and-spine-procedures-100610247","NCT07225101","Evaluation of the Efficacy of STRATAFIX for Neurosurgical Cranial and Spine Procedures","Inclusion Criteria:\n\n* Elective or emergent surgical approaches for cranial or spine neurosurgical approaches, requiring sutures for wound closure, requiring multilayer wound closure\n\nExclusion Criteria:\n\n* Patients with prior surgical wound dehiscence or infection\n* Patients with allergy to suture material",{"count":115,"type":21},160,[117],"PHASE4","This research is studying a device already approved by the Food and Drug Administration (FDA) to treat wound closures. Researchers are studying a large group of people to continue to learn information about the safety of the STRATAFIX suture and how people's bodies react to using it over a long period of time. This research will provide additional information about using STRATAFIX sutures to close surgical wounds.",[120,121,122,123,36,124],"Wound Closure","Brain Tumor Adult","Spine","Neurovascular","Traumatic Brain Injury",[126,127,128,129,130,131,132,133,134],"Superficial surgical site infection","Suture material","Wound closure techniques","brain tumor","spine","spine trauma","neurosurgery","hemorrhagic stroke","traumatic brain injury","2025-11-03",{"date":137,"type":45},"2025-11-05",{"date":139,"type":45},"2025-11-01",{"date":141,"type":21},"2026-12-31",{"name":143,"class":52},"University of Michigan",{"id":145,"slug":146,"hasResults":11,"nctId":147,"briefTitle":148,"officialTitle":149,"acronym":150,"eligibilityCriteria":151,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":152,"enrollmentInfo":153,"targetDuration":4,"studyType":22,"phases":155,"briefSummary":156,"conditions":157,"keywords":160,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":164,"lastUpdatePostDateStruct":165,"startDateStruct":167,"completionDateStruct":169,"leadSponsor":171,"locationsCount":4},"100585215","phase-4-safety-and-feasibility-of-using-cerebrolysin-in-the-treatment-of-primary-intracerebral-hemorrhage---a-prospective-randomized-open-blinded-end-point-trial-100585215","NCT06899464","Safety and Feasibility of Using Cerebrolysin in the Treatment of Primary Intracerebral Hemorrhage - a Prospective Randomized Open Blinded End-point Trial","Safety and Feasibility of Using Cerebrolysin in the Treatment of Primary Intracerebral Hemorrhage","CLINCH","Inclusion Criteria:\n\n* Age 18-80 years\n* NIHSS ≥8 at randomization\n* Stroke onset \\\u003C6h\n* Pre-randomization head CT demonstrating an acute, primary lobar ICH\n* ICH volume 30 to 80 mL\n* Glasgow Coma Score (GCS) 5 to 12\n* Pre-stroke independence (modified Rankin Score 0 to 2)\n* Ability to provide informed consent\n* No history of prior stroke\n\nExclusion Criteria:\n\n* Hemorrhage caused by head trauma\n* Medical history or neuroimaging findings suggestive of ruptured aneurysm, arteriovenous malformation (AVM), vascular anomaly, Moyamoya disease, venous sinus thrombosis, mass or tumor, hemorrhagic conversion of an ischemic infarct\n* Bilateral fixed dilated pupils\n* Extensor motor posturing\n* Intraventricular extension of the hemorrhage is visually estimated to involve \\>50% of either of the lateral ventricles\n* Primary Thalamic and basal ganglia ICH\n* Infratentorial intraparenchymal hemorrhage including midbrain, pontine, or cerebellar\n* Current use of low molecular weight heparins in therapeutic dose\n* Evidence of active bleeding\n* Uncorrected coagulopathy or known clotting disorder\n* Platelet count \\\u003C 75,000, International Normalized Ratio (INR) \\> 1.4 after correction\n* End stage renal disease\n* Patients with a mechanical heart valve\n* End-stage liver disease\n* Epilepsy with grand mal seizures\n* History of drug or alcohol use or dependence that, in the opinion of the site investigator, would interfere with adherence to study requirements\n* Positive urine or serum pregnancy test in female subjects without documented history of surgical sterilization or post-menopausal\n* Known life-expectancy of less than 6 months\n* No reasonable expectation of recovery, Do-Not-Resuscitate (DNR), or comfort measures only prior to randomization\n* Participation in a concurrent interventional medical investigation or clinical trial\n* Inability or unwillingness of subject or legal guardian\u002Frepresentative to give written informed consent\n* Any condition that would represent a contraindication for cerebrolysin administration","80 Years",{"count":154,"type":21},30,[117],"This study is designed to determine the safety and feasibility of using Cerebrolysin in treating primary intracerebral hemorrhage (ICH).\n\nThis is a multicenter, prospective, randomized, open-label, blinded end-point, phase IV parallel group study done in specialized stroke treatment centers in Poland. The study objective is to evaluate if a 14-day cerebrolysin treatment initiated within 6 hours of onset of primary lobar hemorrhage in addition to the standard of care that includes early intensive rehabilitation is safe and feasible, affects hematoma growth and improves the outcome.\n\nThis study is designed to assess the early effect of using Cerebrolysin in patients after ICH, therefore 3 months of follow-up has been chosen. Patients will receive 50 ml of Cerebrolysin once daily until day 14. Subjects will be evaluated on Day 1 (baseline), Day 2, Day 7, Day 30 and Day 90.\n\nEnrollment to the study is expected to reach 30 subjects in 12 months. The study should be completed within 15 months (the end of study).\n\nThe primary outcome measure will be change from baseline in functional independence (mRS 0-2) at Day 90 following stroke onset. The safety outcome will be the number of serious adverse events until Day 30.",[158,36,159,35],"Intracerebral Hemorrhage","Hemorrhagic Stroke",[161,162,163],"Cerebrolysin in stroke","neuroprotection in stroke","Cerebrolysin in hemorrhagic stroke","2025-03-21",{"date":166,"type":45},"2025-03-28",{"date":168,"type":21},"2025-10-01",{"date":170,"type":21},"2027-04-01",{"name":172,"class":52},"Cardinal Stefan Wyszynski University"]